Search > Asthma
110 Participants NeededMy employer runs this trial

HFA-152a vs HFA-134a Inhaler Propellants for Asthma

Recruiting at 12 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: GlaxoSmithKline
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).

Who Is on the Research Team?

GC

GSK Clinical Trials

Principal Investigator

GlaxoSmithKline

Are You a Good Fit for This Trial?

This trial is for adults (18 or older) with a documented history of asthma who use inhalers as needed, possibly along with other common asthma medications. Participants must be stable on their current treatment and meet specific medication use patterns.

Inclusion Criteria

Current non-smokers with no inhaled tobacco or vaping use within 12 months and total pack year history less than or equal to 10; inhaled marijuana prohibited within 12 months prior to study
Demonstrated ability to use pressurized MDI device satisfactorily
Baseline pre-bronchodilator FEV1 greater than or equal to 50% predicted at screening
See 11 more

Exclusion Criteria

Any clinically significant uncontrolled condition or disease that risks participant safety or confounds study results
Known or suspected allergy to salbutamol MDI constituents
Known or suspected history of alcohol or drug abuse
See 14 more

What Are the Treatments Tested in This Trial?

Trial Overview

The study compares the safety of two different propellants used in metered dose inhalers: HFA-152a (new) versus HFA-134a (standard), over a period of four weeks in people with asthma.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Participants receiving HFA-152a followed by HFA-134aExperimental Treatment2 Interventions
Group II: Participants receiving HFA-134a followed by HFA-152aExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley profile image

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron profile image

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.